Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(9)
MIXED(2)
avutometinib (VS-6766)
3 trials
phase_1_2phase_2
verastem-inc
avutometinib (VS-6766) and Defactinib
2 trials
phase_2
verastem-inc
VS-6063
2 trials
phase_1_2phase_2
verastem-inc
avutometinib (VS-6766) and adagrasib
1 trial
phase_1_2
verastem-inc
avutometinib and sotorasib
1 trial
phase_1_2
verastem-inc
avutometinib and sotorasib and defactinib
1 trial
phase_1_2
verastem-inc
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
1 trial
phase_1_2
verastem-inc
7 unique interventions2 categories

Analytics

Trial Phases

Phase 13
Phase 25

Trial Status

Completed2
Other3

Role Distribution

Other Roles5

Activity Timeline

Clinical Trials (5)

NCT05669482Phase 1/2Active Not Recruiting
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
KRAS Activating MutationMalignant Neoplasm of PancreasMetastatic Cancer+2 more
StudydirectorStart date: 2023-03-22
NCT05375994Phase 1/2Completed
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Advanced CancerKRAS Activating MutationMalignant Neoplasm of Lung+3 more
StudydirectorStart date: 2022-08-01
NCT05074810Phase 1/2Active Not Recruiting
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
KRAS Activating MutationNon Small Cell Lung Cancer
StudydirectorStart date: 2022-04-12
NCT04620330Phase 2Completed
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
KRAS Activating MutationNon Small Cell Lung Cancer
StudydirectorStart date: 2020-12-31
NCT04625270Phase 2Active Not Recruiting
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
StudydirectorStart date: 2020-12-21

Research Network

Collaboration Network

5 collaborators·5 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Susana Banerjee, MBBS,MA,PhD

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Moderately Similar
1 trials

Shared therapeutic areas:

Low Grade Ovarian Serous AdenocarcinomaOvary CancerRecurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Worked with same sponsors:

European Network of Gynaecological Oncological Trial Groups (ENGOT)GOG Foundation+1 more
Collaborated on 1 trial
Similarity Score34%

Rachel Grisham, MD

GOG Foundation

Moderately Similar
2 trials

Shared therapeutic areas:

Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)Low Grade Ovarian Serous AdenocarcinomaOvary Cancer

Worked with same sponsors:

European Network of Gynaecological Oncological Trial Groups (ENGOT)GOG Foundation+1 more
Collaborated on 1 trial
Similarity Score34%

Ross Camidge, MD, PhD

University of Colorado, Denver

Related
1 trials

Shared therapeutic areas:

KRAS Activating MutationCarcinoma, Non-Small-Cell Lung

Worked with same sponsors:

Verastem, Inc.
Collaborated on 1 trial
Similarity Score24%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Metastatic CancerCarcinoma, Non-Small-Cell LungOvary Cancer+1 more
Similarity Score10%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

Metastatic CancerOvary CancerCancer of Pancreas

Worked with same sponsors:

Verastem, Inc.
Similarity Score8%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

Related
13 trials

Shared therapeutic areas:

Ovary CancerCarcinoma, Non-Small-Cell LungCancer of Pancreas
Similarity Score8%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Cancer of PancreasCarcinoma, Non-Small-Cell LungOvary Cancer
Similarity Score8%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungCancer of Pancreas
Similarity Score5%

E-mail: ClinicalTrials@ ImClone.com

Eli Lilly and Company

Related
22 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungOvary Cancer
Similarity Score5%

Lin Shen, MD

Peking University Cancer Hospital & Institute

Related
20 trials

Shared therapeutic areas:

Cancer of PancreasAdvanced Cancer
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT05669482Phase 1/2StudyDirector

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

KRAS Activating MutationMalignant Neoplasm of PancreasMetastatic Cancer+2 more
Active Not Recruiting
NCT05375994Phase 1/2StudyDirector

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Advanced CancerKRAS Activating MutationMalignant Neoplasm of Lung+3 more
Completed
NCT05074810Phase 1/2StudyDirector

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

KRAS Activating MutationNon Small Cell Lung Cancer
Active Not Recruiting
NCT04620330Phase 2StudyDirector

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

KRAS Activating MutationNon Small Cell Lung Cancer
Completed
NCT04625270Phase 2StudyDirector

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Active Not Recruiting

All 5 trials loaded